Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PREP | P48147 | 7/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28928462 | 0.92 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL28928464 | 0.92 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL7286213 | 0.88 | PREP (0.55) | SMN1; SMN2NPC1RAB9APREPACE2 | |
| SCHEMBL7286320 | 0.88 | PREP (0.55) | SMN1; SMN2NPC1RAB9APREPACE2 | |
| SCHEMBL1437422 | 0.87 | PREP (0.69) | PREP | |
| SCHEMBL943473 | 0.87 | PREP (0.69) | PREP | |
| SCHEMBL1437419 | 0.87 | PREP (0.69) | PREP | |
| SCHEMBL28779768 | 0.84 | PREP (0.51) | SMN1; SMN2NPC1RAB9APREPACE2 | |
| SCHEMBL4959347 | 0.83 | PREP (0.65) | PREP | |
| SCHEMBL812253 | 0.82 | PREP (0.57) | SMN1; SMN2NPC1RAB9APREPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008070447-A2 | ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | SMN1; SMN2 441/4885NPC1 981/4885RAB9A 1092/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | SMN1; SMN2 441/4885NPC1 981/4885RAB9A 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.